P05 (a 61 years male ever-smoker) with stage IIB lung squamous cell carcinoma (LUSC) who harbored no actionable alterations but had PD-L1 expression (TPS: 5% in the surgical sample and 30% in the CNB sample) received platinum plus paclitaxel and a programmed cell death protein 1 (PD-1) inhibitor pembrolizumab as adjuvant therapy. This evidence concerns the gene CD274 and squamous cell lung carcinoma.